Misty Cundiff, APRN
Family · Monticello, KYNPI 1497178347
Payments from drug & device makers
Across 565 payments — averaging $12.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$766
- Lilly USA, LLC$690
- Novo Nordisk$609
- AbbVie$518
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$508
- AstraZeneca$431
- plus $4K from 30 others
What the payments were for
- Food & beverage$7,14898%
- Education$1662%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 90 | $766 |
| Lilly USA, LLC | 53 | $690 |
| Novo Nordisk | 52 | $609 |
| AbbVie | 43 | $518 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 53 | $508 |
| AstraZeneca | 22 | $431 |
| Pfizer | 39 | $377 |
| Amgen(2 entities) | 20 | $280 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $266 |
| Biohaven Pharmaceuticals, Inc. | 20 | $255 |
| Ironshore Pharmaceuticals Inc. | 13 | $243 |
| Astellas Pharma US Inc | 6 | $218 |
| Biohaven Pharmaceutical Holding Company Ltd. | 21 | $201 |
| Vanda Pharmaceuticals Inc. | 13 | $194 |
| GSK | 11 | $189 |
| Novartis | 8 | $177 |
| Abbott | 9 | $164 |
| Bayer | 9 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $122 |
| Axsome Therapeutics, Inc. | 6 | $105 |
| Supernus Pharmaceuticals, Inc. | 5 | $93 |
| Merck | 5 | $86 |
| Mylan Specialty L.p. | 5 | $86 |
| Alkermes, Inc. | 4 | $81 |
| Boehringer Ingelheim | 6 | $79 |
| Sanofi-aventis U.S. LLC | 4 | $72 |
| Xeris Pharmaceuticals, Inc. | 4 | $70 |
| Almatica Pharma LLC | 3 | $63 |
| Lundbeck LLC | 3 | $48 |
| Sunovion Pharmaceuticals Inc. | 4 | $45 |
| Phathom Pharmaceuticals, Inc. | 3 | $30 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Dexcom, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $17 |
| Exact Sciences | 1 | $14 |
How this compares
$7,314 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 259 | $313,515 |
| OzempicSemaglutide | 134 | $133,631 |
| RexultiBrexpiprazole | 75 | $122,017 |
| XifaxanRifaximin | 31 | $113,471 |
| FarxigaDapagliflozin Propanediol | 124 | $112,739 |
| Nurtec OdtRimegepant Sulfate | 46 | $82,604 |
| JardianceEmpagliflozin | 87 | $80,927 |
| LinzessLinaclotide | 121 | $77,631 |
| EliquisApixaban | 97 | $70,642 |
| Xeljanz XrTofacitinib Citrate | 11 | $63,950 |
| Praluent PenAlirocumab | 115 | $57,361 |
| JanuviaSitagliptin Phosphate | 58 | $47,053 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $43,746 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 56 | $37,626 |
| Repatha SureclickEvolocumab | 62 | $35,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $690 | $313,515259 claims |
| Novo NordiskOzempic, Rybelsus | $609 | $165,366165 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $431 | $164,014211 claims |
| PfizerNurtec Odt, Eliquis | $377 | $153,247143 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Synjardy Xr, Tradjenta, Synjardy | $79 | $128,998164 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $508 | $128,51758 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $766 | $122,01775 claims |
| AbbVieLinzess, Viberzi | $518 | $87,072133 claims |
| MerckJanuvia | $86 | $47,05358 claims |
| BayerKerendia | $155 | $23,66137 claims |
| Johnson & JohnsonXarelto | $17 | $20,63434 claims |
| GSKTrelegy Ellipta | $189 | $20,15926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Monticello
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.